Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
CHST3 encodes chondroitin 6-O-sulfotransferase 1, which catalyzes sulfation of chondroitin sulfate in cartilage. Biallelic CHST3 mutations cause autosomal recessive spondyloepiphyseal dysplasia with congenital joint dislocations (SDCD) characterized by knee, hip, and elbow dislocations at birth, clubfoot, short stature, and progressive kyphoscoliosis. Genetic testing of CHST3 is critical for differential diagnosis among congenital dislocation syndromes.
Over 52 probands ([PMID:18513679]; [PMID:20830804]; [PMID:32639237]; [PMID:37183573]) from ≥23 unrelated families ([PMID:20830804]; [PMID:32639237]; [PMID:37183573]), consistent autosomal recessive segregation, and concordant loss-of-function and enzymatic impairment data ([PMID:15215498]; [PMID:19320654]) support a Definitive gene–disease association.
Inheritance is autosomal recessive. Reported variants include eight nonsense/frameshift alleles (e.g., c.83T>A (p.Leu28Ter) [PMID:18513679]), multiple missense substitutions (e.g., c.665G>A (p.Arg222Gln) [PMID:18513679]), small insertions (c.58_77dup (p.Leu26_Phe27insTer) [PMID:18513679]), and recurrent founder alleles c.776T>C (p.Leu259Pro) in Turkish patients ([PMID:32639237]) and c.384_391dup (p.Pro131ArgfsTer88) in Egyptian families ([PMID:37183573]). A total of 24 unique CHST3 mutations have been described across cohorts.
Recombinant enzyme assays demonstrate that the p.Arg304Gln mutation abolishes sulfotransferase activity and markedly reduces 6-O-sulfation of chondroitin sulfate chains in patient cells ([PMID:15215498]). The p.Thr141Met substitution reduces C6ST-1 activity to 24–29% of wild type and correlates with severe spinal involvement and cardiac lesions ([PMID:19320654]). Dermal fibroblast studies show decreased 6-O- and compensatory increase in 4-O-sulfation.
Loss of CHST3 activity results in defective proteoglycan sulfation, compromising cartilage matrix integrity and leading to congenital joint instability. Radiographic hallmarks include platyspondyly, flared metaphyses, epiphyseal dysplasia, and kyphoscoliosis developing in late childhood. Extraskel etal features such as clubfoot, rhizomelia, hearing impairment, microdontia, and atrial septal defect may be observed.
Robust genetic and functional data establish CHST3 deficiency as the cause of SDCD. CHST3 sequencing should be offered to patients with congenital large-joint dislocations and characteristic radiographic changes. Early molecular diagnosis enables accurate genetic counseling and anticipatory management of skeletal and cardiac complications.
Key take-home: Biallelic CHST3 variants definitively cause autosomal recessive SDCD and warrant targeted genetic testing for precise diagnosis and management.
Gene–Disease AssociationDefinitiveOver 52 probands ([PMID:18513679]; [PMID:20830804]; [PMID:32639237]; [PMID:37183573]) in ≥23 unrelated families ([PMID:20830804]; [PMID:32639237]; [PMID:37183573]), consistent AR segregation, and concordant functional impairment ([PMID:15215498]; [PMID:19320654]) Genetic EvidenceStrong52 probands with biallelic CHST3 variants across multiple studies; LoF and missense alleles in AR pattern; recurrent founder variants identified Functional EvidenceModerateRecombinant assays show abolished or reduced sulfotransferase activity for p.Arg304Gln and p.Thr141Met; patient fibroblast studies confirm defective 6-O-sulfation |